{"schema_version":"1.0","type":"article","title":"合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.md","lang":"zh-Hant","date":"2026-07-02","publish_at":"2026-07-02T10:30:00+08:00","updated_at":"2026-07-02","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。","key_points":[],"facts":[],"sections":["01｜合成致死為什麼迷人？因為它只打癌細胞的「第二條命」","02｜為什麼 PARP 難複製？因為多數合成致死關係沒有那麼單純","03｜第一個轉機：合成致死不一定要做成單藥，聯合療法可能更有價值","04｜第二個轉機：PROTAC 與分子膠，開始解鎖過去不能成藥的靶點","05｜第三個轉機：biomarker 必須更精準，否則臨床會被稀釋","06｜台灣可以怎麼看？重點不是做下一個 PARP，而是檢測與精準分層","結語｜合成致死沒有失敗，只是從單藥神話走向精準組合"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":"https://www.coherentmarketinsights.com/"},{"title":"[2]:","source":"","date":"","url":"https://oncodaily.com/"},{"title":"[3]:","source":"","date":"","url":"https://ir.reparerx.com/"},{"title":"[4]:","source":"","date":"","url":"https://www.fiercebiotech.com/"},{"title":"[5]:","source":"","date":"","url":"https://www.debiopharm.com/"}],"images":[{"alt":"Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 1）","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-01.png"},{"alt":"Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 2）","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-02.png"},{"alt":"Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 3）","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-03.png"},{"alt":"Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 4）","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-02）。合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？。https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}